Robert Hazlett
Stock Analyst at BTIG
(1.30)
# 3,662
Out of 5,127 analysts
23
Total ratings
39.13%
Success rate
-1.45%
Average return
Main Sectors:
Stocks Rated by Robert Hazlett
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AURA Aura Biosciences | Maintains: Buy | $21 → $24 | $5.63 | +326.29% | 3 | Oct 18, 2024 | |
| NKTR Nektar Therapeutics | Assumes: Buy | $60 | $56.00 | +7.14% | 2 | Sep 30, 2024 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $7 → $14 | $1.34 | +944.78% | 2 | May 9, 2024 | |
| LYRA Lyra Therapeutics | Maintains: Buy | $1,200 → $1,000 | $1.47 | +67,927.21% | 1 | Feb 7, 2023 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $62 → $98 | $184.30 | -46.83% | 2 | Dec 23, 2022 | |
| VSTM Verastem | Maintains: Buy | $96 → $60 | $6.28 | +855.41% | 3 | Oct 5, 2022 | |
| CMPS COMPASS Pathways | Initiates: Buy | $63 | $6.29 | +901.59% | 1 | May 27, 2021 | |
| PRTA Prothena Corporation | Upgrades: Buy | $29 | $8.96 | +223.66% | 4 | Feb 2, 2021 | |
| RDHL RedHill Biopharma | Initiates: Buy | $26,000 | $1.00 | +2,606,155.01% | 1 | Sep 11, 2020 | |
| AKBA Akebia Therapeutics | Maintains: Buy | $26 → $6 | $1.51 | +297.35% | 2 | Sep 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $14.99 | +20.08% | 2 | Aug 31, 2017 |
Aura Biosciences
Oct 18, 2024
Maintains: Buy
Price Target: $21 → $24
Current: $5.63
Upside: +326.29%
Nektar Therapeutics
Sep 30, 2024
Assumes: Buy
Price Target: $60
Current: $56.00
Upside: +7.14%
Rani Therapeutics Holdings
May 9, 2024
Maintains: Buy
Price Target: $7 → $14
Current: $1.34
Upside: +944.78%
Lyra Therapeutics
Feb 7, 2023
Maintains: Buy
Price Target: $1,200 → $1,000
Current: $1.47
Upside: +67,927.21%
Axsome Therapeutics
Dec 23, 2022
Maintains: Buy
Price Target: $62 → $98
Current: $184.30
Upside: -46.83%
Verastem
Oct 5, 2022
Maintains: Buy
Price Target: $96 → $60
Current: $6.28
Upside: +855.41%
COMPASS Pathways
May 27, 2021
Initiates: Buy
Price Target: $63
Current: $6.29
Upside: +901.59%
Prothena Corporation
Feb 2, 2021
Upgrades: Buy
Price Target: $29
Current: $8.96
Upside: +223.66%
RedHill Biopharma
Sep 11, 2020
Initiates: Buy
Price Target: $26,000
Current: $1.00
Upside: +2,606,155.01%
Akebia Therapeutics
Sep 4, 2020
Maintains: Buy
Price Target: $26 → $6
Current: $1.51
Upside: +297.35%
Aug 31, 2017
Initiates: Buy
Price Target: $18
Current: $14.99
Upside: +20.08%